Candel Therapeutics Reports Extended Survival in NSCLC Trial, Setting Stage for Phase 3
Event summary
- 50% of 46 advanced NSCLC patients treated with aglatimagene survived beyond 24 months, despite prior ICI failure.
- 85% of long-term survivors had baseline PD-L1 TPS below 50%, suggesting aglatimagene converts 'cold' tumors to immune-active.
- Median overall survival (mOS) reached 25.4 months in evaluable patients, a two-fold improvement over historical controls.
- Phase 3 trial initiation planned for Q2 2026, with FDA Fast Track designation already secured.
The big picture
Candel Therapeutics' updated data reinforces the potential of aglatimagene to address a critical unmet need in NSCLC patients who fail immune checkpoint inhibitors. The results align with broader industry trends toward multimodal immunotherapies that convert non-responsive tumors into immune-active environments. The planned phase 3 trial could position Candel as a key player in precision oncology, particularly if the survival benefits are replicated at scale.
What we're watching
- Clinical Validation
- Whether the extended survival tail observed in the phase 2a trial will translate into statistically significant outcomes in the planned phase 3 study.
- Regulatory Pathway
- The pace at which the FDA will advance aglatimagene through its accelerated review process, given the Fast Track designation.
- Market Differentiation
- How Candel Therapeutics positions aglatimagene against existing and emerging therapies for ICI-resistant NSCLC.
Related topics